QOP
CAPR icon

Quinn Opportunity Partners’s Capricor Therapeutics CAPR Stock Holding History

Quinn Opportunity Partners’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.08M Sell
44,698
-133,685
-75% -$4.05M 0.05% 219
2026
Q1 		$5.42M Sell
178,383
-64,500
-27% -$1.72M 0.28% 86
2025
Q4 		$7.01M Buy
242,883
+114,545
+89% +$1.5M 0.3% 84
2025
Q3 		$925K Buy
+128,338
New +$945K 0.07% 195

Other funds holding CAPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Quinn Opportunity Partners's CAPR Position: Q2 2026 in Review

Quinn Opportunity Partners reduced its Capricor Therapeutics (CAPR) stake by 75% in Q2 2026, selling an estimated $4.05M and leaving 44,698 shares worth $1.08M. The position accounts for 0.05% of the portfolio, ranked #219.

Quinn Opportunity Partners first reported a position in CAPR in Q3 2025 and has held it in 4 quarters since. The position peaked at $7.01M in Q4 2025. 169 funds tracked by Wall St. Rank hold CAPR as of Q2 2026.

  • Quinn Opportunity Partners held 44,698 shares of Capricor Therapeutics worth $1.08M as of Q2 2026.
  • Quinn Opportunity Partners sold 133,685 Capricor Therapeutics shares in Q2 2026, an estimated $4.05M.
  • Capricor Therapeutics made up 0.05% of Quinn Opportunity Partners's portfolio in Q2 2026, its #219 holding.
  • Quinn Opportunity Partners first reported a position in Capricor Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Quinn Opportunity Partners's Capricor Therapeutics position peaked at $7.01M in Q4 2025.
  • 169 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2026.

Based on Quinn Opportunity Partners's 13F filing for Q2 2026, filed 14 Aug 2026.